Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada

Bulletin of the World Health Organization

Volumn 74, Issue 4, 1996, Pages 407-411

  De Wals, P ^a,b   Dionne, M ^c   Douville Fradet, M ^c   Boulianne, N ^c   Drapeau, J ^d   De Serres, G ^c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b Dir de la S Pub de la Monteregie   (Canada)

^c Ctr de S Pub de Quebec   (Canada)

^d CHUS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; CANADA; CONTROLLED STUDY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MENINGITIS; NEISSERIA MENINGITIDIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; HUMANS; IMMUNIZATION; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; QUEBEC;

DISEASE INCIDENCE; IMMUNISATION IMPACT; MENINGOCOCCAL DISEASE;

CANADA, QUEBEC;

EID: 0029659868     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ashton FE et al. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. Journal of clinical microbiology. 1991, 29: 2489-2493.
2. Whalen CM et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Journal of the American Medical Association, 1995, 273: 390-394.
3. Jackson LA et al. Serogroup C meningococcal outbreaks in the United States. Journal of the American Medical Association, 1995, 273: 383-389.
4. Advisory Committee on Epidemiology. Canadian communicable disease surveillance system. Canada diseases weekly report, 1991, 17(suppl. 3): 29-30.
5. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV Immunogenicity of group A and group C meningococcal polysaccharide in human volunteers. Journal of experimental medicine, 1969, 129: 1385-1395.
6. Longini IM, Halloram ME, Haber M. Measuring vaccine efficacy from epidemics of acute infectious agents. Statistics in medicine, 1993, 12: 249-263.
7. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-1970. Bulletin of the World Health Organization, 1971, 45: 279-282.
8. Taunay AE et al. [Evaluation of the protective effect of anti-meningococcal serogroup C polysaccharide vaccine in children aged 6-36 months.] Revista do Instituto Adolfo Lutz, 1978, 32: 77-82 (in Portuguese).
9. Yergeau A et al. Adverse events temporally associated with meningococcal vaccines. Canadian Medical Association journal, 1996, 154: 503-507.
10. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. Journal of experimental medicine, 1969, 129: 1367-1395.
11. Artenstein MS et al. Prevention of meningococcal disease by group C polysaccharide vaccine. New England journal of medicine, 1970, 282: 417-420.
12. Devine LF et al. Evaluation of group C meningococcal polysaccharide vaccine in Marine recruits, San Diego, California. American journal of epidemiology, 1970, 92: 25-32.